Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from ZYUS Life Sciences ( (TSE:ZYUS) ).
ZYUS Life Sciences announced the closing of the second tranche of its non-brokered private placement, raising a total of approximately CAD $0.42 million. The proceeds will be used for general corporate and working capital purposes, with the offering receiving conditional approval from the TSX Venture Exchange. This financial move supports ZYUS’s strategic goals in the cannabinoid-based pharmaceutical industry, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to advancing scientific exploration and clinical research to secure intellectual property protection and regulatory approval for non-opioid-based pharmaceutical solutions, aiming to transform patient care.
Average Trading Volume: 15,279
Technical Sentiment Signal: Sell
Current Market Cap: C$48.6M
Find detailed analytics on ZYUS stock on TipRanks’ Stock Analysis page.